A Study of 1592U89 in HIV-Infected Patients
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects|
Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All patients receive 12 weeks of monotherapy during the initial 12-week treatment phase.
On completion of the treatment phase, patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002388
|United States, Illinois|
|Evanston Hosp / Clinical Pharmacology Unit|
|Evanston, Illinois, United States, 60201|
|United States, Massachusetts|
|Fenway Community Health Ctr / Research Dept|
|Boston, Massachusetts, United States, 02115|
|United States, New York|
|Albany Med College / Albany Med Ctr Hosp|
|Albany, New York, United States, 12208|